Renal & Urology News

Minimal Priapism Risk with AndroGel 1% Use

Testosterone replacement with 1% testosterone gel (AndroGel 1%) is rarely associated with the development of priapism, according to a study. Arthur L. Burnett, MD, of Johns Hopkins University in ...
AOL

AbbVie wins reversal of $140 mln verdict in case over AndroGel risks

July 5 (Reuters) - A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone ...
Time

Testosterone Treatments Aren’t Linked to Heart Risks When Patients Are Carefully Monitored, Study Finds

Advertisements for treatments for “low T,” or low testosterone levels in middle-aged and older men, have led to spikes in demand. But the safety and legitimacy of those testosterone therapies hasn’t ...
Reuters

U.S. jury finds AbbVie liable for misrepresentation in AndroGel verdict

NEW YORK (Reuters) - A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 ...
Healio

Focus on CV risk, T Trials follows 20-year rise in testosterone use

Please provide your email address to receive an email when new articles are posted on . During the past 2 decades, Endocrine Today has reported on the latest developments in testosterone therapy, ...